Cardiol Therapeutics Inc. (CRDL)
NASDAQ: CRDL · Real-Time Price · USD
1.370
-0.030 (-2.14%)
At close: Apr 28, 2026, 4:00 PM EDT
1.363
-0.007 (-0.53%)
After-hours: Apr 28, 2026, 7:58 PM EDT
Cardiol Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
18
Market Cap
152.14M USD
Revenue Chart
* This company reports financials in CAD.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Organogenesis Holdings | 564.17M |
| Aurora Cannabis | 272.13M |
| Organigram Global | 204.21M |
| Lifecore Biomedical | 129.46M |
| Assertio Holdings | 118.71M |
| Anika Therapeutics | 112.82M |
| SIGA Technologies | 94.57M |
| Journey Medical | 61.86M |
CRDL News
- 18 hours ago - Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program - PRNewsWire
- 14 days ago - Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart - Newsfile Corp
- 22 days ago - Cardiol Therapeutics (CRDL) Receives 'Buy' Rating from Canaccord Genuity | CRDL Stock News - GuruFocus
- 27 days ago - Cardiol Therapeutics Announces Year-End 2025 Update on Operations - Newsfile Corp
- 7 weeks ago - Cardiol Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
- 2 months ago - Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference - Newsfile Corp
- 2 months ago - Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure - Newsfile Corp
- 3 months ago - Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million - Newsfile Corp